Whalen Wealth Management Inc. Makes New Investment in Elanco Animal Health Incorporated $ELAN

Whalen Wealth Management Inc. purchased a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 21,814 shares of the company’s stock, valued at approximately $537,000.

Other large investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Elanco Animal Health during the first quarter worth about $2,065,000. Goldman Sachs Group Inc. increased its holdings in Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Empowered Funds LLC increased its holdings in Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after buying an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Elanco Animal Health by 4.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after acquiring an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Elanco Animal Health by 2,006.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after acquiring an additional 295,651 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 1.8%

ELAN stock opened at $24.41 on Tuesday. The company’s 50 day simple moving average is $24.56 and its 200-day simple moving average is $24.00. The firm has a market capitalization of $12.20 billion, a PE ratio of -59.54, a P/E/G ratio of 1.44 and a beta of 1.67. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same period last year, the company posted $0.26 EPS. The company’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELAN. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday. Citigroup lifted their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. KeyCorp boosted their target price on Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, TD Cowen raised their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.09.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius acquired 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the purchase, the director directly owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the transaction, the chief financial officer owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 63,198 shares of company stock valued at $1,473,109. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.